Cargando...
A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer
PURPOSE: To assess the maximum well-tolerated dose (MWTD), dose limiting toxicity (DLT), antitumor activity, pharmacokinetics and pharmacodynamics of ZD4054, a novel specific endothelin-A (ET(A)) receptor antagonist, in patients with metastatic prostate cancer. EXPERIMENTAL DESIGN: Patients with met...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2009
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3008512/ https://ncbi.nlm.nih.gov/pubmed/19763400 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-009-9318-5 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|